DE60322946D1 - Tetrahydronaphtalen-derivate als vanilloid-rezeptor-antagonisten - Google Patents

Tetrahydronaphtalen-derivate als vanilloid-rezeptor-antagonisten

Info

Publication number
DE60322946D1
DE60322946D1 DE60322946T DE60322946T DE60322946D1 DE 60322946 D1 DE60322946 D1 DE 60322946D1 DE 60322946 T DE60322946 T DE 60322946T DE 60322946 T DE60322946 T DE 60322946T DE 60322946 D1 DE60322946 D1 DE 60322946D1
Authority
DE
Germany
Prior art keywords
derivatives
pain
tetrahydronaphtalen
receptor antagonists
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322946T
Other languages
English (en)
Inventor
Masaomi Tajimi
Toshio Kokubo
Masahiro Shiroo
Yasuhiro Tsukimi
Takeshi Yura
Noriyuki Yamamoto
Muneto Mogi
Hiroshi Fujishima
Tsutomu Masuda
Nagahiro Yoshida
Toshiya Moriwaki
Klaus Urbahns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xention Ltd
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xention Ltd filed Critical Xention Ltd
Application granted granted Critical
Publication of DE60322946D1 publication Critical patent/DE60322946D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
DE60322946T 2002-12-09 2003-11-28 Tetrahydronaphtalen-derivate als vanilloid-rezeptor-antagonisten Expired - Lifetime DE60322946D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02027528 2002-12-09
PCT/EP2003/013452 WO2004052845A1 (en) 2002-12-09 2003-11-28 Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists

Publications (1)

Publication Number Publication Date
DE60322946D1 true DE60322946D1 (de) 2008-09-25

Family

ID=32479714

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322946T Expired - Lifetime DE60322946D1 (de) 2002-12-09 2003-11-28 Tetrahydronaphtalen-derivate als vanilloid-rezeptor-antagonisten

Country Status (11)

Country Link
US (2) US7544716B2 (de)
EP (1) EP1572632B1 (de)
JP (1) JP4440113B2 (de)
AT (1) ATE404531T1 (de)
AU (1) AU2003288200A1 (de)
CA (1) CA2508845C (de)
DE (1) DE60322946D1 (de)
DK (1) DK1572632T3 (de)
ES (1) ES2311744T3 (de)
PT (1) PT1572632E (de)
WO (1) WO2004052845A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528164B2 (en) * 2002-05-16 2009-05-05 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2003294748A1 (en) * 2002-12-06 2004-06-30 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
PT1572632E (pt) * 2002-12-09 2008-09-19 Xention Ltd Derivados de tetra-hidro-naftaleno como antagonistas do receptor vanilóide
WO2004092136A1 (ja) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその用途
CA2540647C (en) * 2003-10-01 2012-07-10 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
WO2005035471A1 (ja) 2003-10-14 2005-04-21 Ajinomoto Co., Inc. エーテル誘導体
US20080045546A1 (en) * 2003-10-15 2008-02-21 Axel Bouchon Tetradydro-Naphthalene And Urea Derivatives
WO2005044802A2 (en) 2003-11-08 2005-05-19 Bayer Healthcare Ag Tetrahydro-quinolinylurea derivatives as vrl antagonists
CA2599778A1 (en) * 2005-03-05 2006-09-14 Bayer Healthcare Ag Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases
DE102005023944A1 (de) * 2005-05-20 2006-11-23 Grünenthal GmbH Substituierte benzokondensierte Cycloheptanon-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
US20090197966A1 (en) * 2006-10-04 2009-08-06 Uno Jakob Weber Use of Hypothermia Inducing Drugs
CN101563318A (zh) * 2006-12-20 2009-10-21 艾博特公司 作为trpv1香草素受体拮抗剂用于治疗疼痛的n-(5,6,7,8-四氢萘-1-基)脲衍生物以及相关化合物
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004763A (en) 1932-06-11 1935-06-11 Du Pont N (p-amino-phenyl) morpholine and method of preparing the same
US3142699A (en) * 1958-04-24 1964-07-28 Bayer Ag Urethane compounds and process therefor
DE1187791B (de) * 1962-02-03 1965-02-25 Bayer Ag Die Verwendung von organischen Salzen als verkappte Beschleuniger fuer Isocyanatreaktionen
US3878206A (en) 1973-06-06 1975-04-15 Morton Norwich Products Inc 9-(Substituted amino)imidazo{8 4,5-f{9 quinolines
US4443473A (en) * 1981-06-30 1984-04-17 The Procter & Gamble Company Carbamate derivatives
US4477389A (en) * 1982-10-25 1984-10-16 The United States Of America As Represented By The Secretary Of Agriculture Polyhalogenated phenyl isocyanate synthesis with excess phosgene and either triethylamine or tetramethylurea
WO1990012797A1 (en) 1989-04-19 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sulfer-containing xanthine derivatives as adenosin antagonists
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6103708A (en) 1998-05-12 2000-08-15 American Home Products Corporation Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6476076B1 (en) * 1999-02-22 2002-11-05 Pacific Corporation Vanilloid analogues containing resinferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
DE60023853T2 (de) * 1999-03-12 2006-05-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
US6294694B1 (en) * 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
AU769834B2 (en) 1999-08-10 2004-02-05 Ihara Chemical Industry Co. Ltd. Isoxazoline derivatives and herbicides containing the same as the active ingredient
JP2001322988A (ja) 2000-03-09 2001-11-20 Nippon Bayer Agrochem Co Ltd 殺センチュウ性トリフルオロブテン類
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
GB0105895D0 (en) * 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
CA2455754A1 (en) * 2001-07-31 2003-02-20 Bayer Healthcare Ag Amine derivatives
ES2316777T3 (es) * 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
EP1506167B1 (de) * 2002-05-08 2007-08-29 Bayer HealthCare AG Hydroxy-tetrahydro-naphtalenylharnstoff-derivate
AU2003251828A1 (en) * 2002-07-12 2004-02-02 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
US7223866B2 (en) 2002-11-18 2007-05-29 Novartis Ag Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases
AU2003294748A1 (en) * 2002-12-06 2004-06-30 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
PT1572632E (pt) * 2002-12-09 2008-09-19 Xention Ltd Derivados de tetra-hidro-naftaleno como antagonistas do receptor vanilóide
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CA2540647C (en) * 2003-10-01 2012-07-10 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7553848B2 (en) * 2004-01-23 2009-06-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments

Also Published As

Publication number Publication date
PT1572632E (pt) 2008-09-19
ATE404531T1 (de) 2008-08-15
WO2004052845A1 (en) 2004-06-24
US20060135505A1 (en) 2006-06-22
EP1572632B1 (de) 2008-08-13
EP1572632A1 (de) 2005-09-14
AU2003288200A8 (en) 2004-06-30
CA2508845A1 (en) 2004-06-24
AU2003288200A1 (en) 2004-06-30
WO2004052845A8 (en) 2005-06-09
DK1572632T3 (da) 2008-10-27
CA2508845C (en) 2012-02-21
JP2006509017A (ja) 2006-03-16
JP4440113B2 (ja) 2010-03-24
ES2311744T3 (es) 2009-02-16
US20090209514A1 (en) 2009-08-20
US7544716B2 (en) 2009-06-09

Similar Documents

Publication Publication Date Title
HK1082946A1 (en) Hydroxy tetrahydro-naphthalenyurea derivatives
DK1569896T3 (da) Tetrahydronaphthalenderivater
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
ATE404531T1 (de) Tetrahydronaphtalen-derivate als vanilloid- rezeptor-antagonisten
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
WO2005044802A3 (en) Tetrahydro-quinolinylurea derivatives as vrl antagonists
ECSP045413A (es) "derivados de hidroxi-tetrahidro-naftalenilurea"
UY27794A1 (es) Derivados de hidroxi tetrahidro-naftalenilurea
TH78306A (th) อนุพันธ์ไฮดรอกซีเททตราไฮโดร-แนพธาลีนิลยูเรีย
TH78306B (th) "อนุพันธ์ไฮดรอกซีเททตราไฮโดร-แนพธาลีนิลยูเรีย"

Legal Events

Date Code Title Description
8364 No opposition during term of opposition